Delivery Order VA25913D0313-VA25915J4600

The National Institutes of Health National Institute on Drug Abuse awarded a $288,375 firm fixed price purchase order to Curia Global Inc., doing business as Amri, to provide non-GMP synthesis of up to 100 ligands that bind the KIAA0203 protein. Under the terms of the contract, Amri will synthesize the ligands in 2-10 milligram quantities over a one-year period of performance. Amri must dedicate two full-time scientists and one part-time scientist at 25% effort to update progress. There is no...

The National Institute on Drug Abuse awarded a definitive contract to Research Triangle Institute for analytical chemistry and stability testing of treatment drugs for substance use disorders on August 4, 2024, with a ceiling value of $7,017,379 and no set-aside. The originating solicitation required offerors to possess DEA Research Registration for Schedules II through V and the ability to obtain Schedule I registration, along with cGMP-compliant manufacturing facilities inspected by the FDA...

The Department of Health and Human Services Food and Drug Administration awarded a definitive contract valued at $831,964 to Research Center Pharmaceutical Engineering GmbH. The firm fixed price contract is to provide services in support of the project titled "OCT for Real-Time Monitoring of Coating Process Dynamics & Product Quality" and will involve work by the prime contractor and its parent organization, Technische Universitaet Graz. The contract has a period of performance...

The National Institute on Drug Abuse issued a delivery order to Mriglobal (doing business as Midwest Research Institute) on July 20, 2026, with a ceiling value of $382,839, under a cost-plus-fixed-fee pricing structure for Phase 1 single ascending dose pharmacokinetics study analytical services. The order runs through January 19, 2028. Place of performance is Kansas City, Missouri. This task order (DAP-NCAP-00000009) supports the Analytical Services Center for Medications Development, part of...

This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated...

This federal contract award to PPD Development LP, a global contract research organization (CRO), provides regulatory consulting assistance for a medical device developer under the Blueprint MedTech program. The $370,621 cost-plus-fixed-fee contract includes research and development for clinical studies, pre-submission assessment, and package preparation. The award is issued by the National Institute on Drug Abuse, a civilian agency, and is not set aside. PPD Development LP is a subsidiary of...

The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a firm fixed-price purchase order valued at $22,500 to the University of Kansas Center for Research, Inc. This award is pursuant to a request for quote to develop a manufacturable tablet formulation of the compound NCGC72 for use in dog sarcoma clinical studies. The prime contractor will non-GMP manufacture 1,500 tablets total, with 1,000 tablets at 50mg dosage and 500 tablets at...

This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...

The National Institute on Drug Abuse awarded a delivery order valued at $827,787.59 to Bachem Americas Inc. for the manufacture of 1 kilogram of current Good Manufacturing Practice (cGMP) L-enkephalin (L-ENK) and related contract research organization (CRO) support services for drug substance development and manufacturing. The award was issued on September 18, 2020, with an ultimate completion date of August 31, 2024. This delivery order falls under Bachem Americas' larger Indefinite...

The Food and Drug Administration awarded a $1.3 million definitive contract on September 24, 2024, to PPD Development LP for research understanding heterogeneity in preferences for clinical trial participation in diverse patient populations. Structured as a time and materials contract with an ultimate completion date of November 22, 2027, the award will be performed in Cape Fear, North Carolina. This contract supports FDA's mission to ensure safe and effective medical products by examining how...